HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $9 Price Target

Benzinga · 05/10 11:51
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Regulus Therapeutics (NASDAQ:RGLS) with a Buy and maintains $9 price target.